Carnegie acted as adviser to Karo Bio in a rights issue of approximately SEK 125 million. Karo Bio develops drugs based on nuclear receptor mechanisms.May, 2003.
Healthcare
Rights issue in Karo Bio (SE) — SEK 125 million
May 2003